Keith L. Shulman

472 total citations
14 papers, 347 citations indexed

About

Keith L. Shulman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Keith L. Shulman has authored 14 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Keith L. Shulman's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Keith L. Shulman is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Keith L. Shulman collaborates with scholars based in United States, Israel and Germany. Keith L. Shulman's co-authors include Hedy L. Kindler, Han‐Mou Tsai, John A. Thompson, Mark Benyunes, Richard L. Schilsky, S. David Stulberg, P.H. Lange, A Fefer, Catherine Lindgren and William H. Bush and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The American Journal of Sports Medicine.

In The Last Decade

Keith L. Shulman

13 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith L. Shulman United States	9	164	113	65	62	52	14	347
Rahul Hejmadi United Kingdom	12	136 0.8×	91 0.8×	89 1.4×	59 1.0×	78 1.5×	34	384
Mitsuru Yoshimoto Japan	10	179 1.1×	37 0.3×	69 1.1×	31 0.5×	138 2.7×	37	436
Shinya Maita Japan	10	137 0.8×	46 0.4×	82 1.3×	146 2.4×	109 2.1×	25	370
Suna Çokmert Türkiye	10	218 1.3×	47 0.4×	49 0.8×	70 1.1×	28 0.5×	30	291
Lena Innala Sweden	7	42 0.3×	105 0.9×	29 0.4×	34 0.5×	74 1.4×	11	630
Yunyun Fei China	9	44 0.3×	148 1.3×	15 0.2×	42 0.7×	71 1.4×	14	368
Hiroto Horiguchi Japan	9	124 0.8×	46 0.4×	43 0.7×	59 1.0×	99 1.9×	29	336
Miriam Quitt Israel	11	67 0.4×	39 0.3×	49 0.8×	45 0.7×	59 1.1×	31	299
Ed Keystone Canada	11	74 0.5×	147 1.3×	38 0.6×	12 0.2×	98 1.9×	25	572
Jodi Lyn Layton United States	7	90 0.5×	120 1.1×	97 1.5×	130 2.1×	37 0.7×	40	350

Countries citing papers authored by Keith L. Shulman

Since Specialization

Citations

This map shows the geographic impact of Keith L. Shulman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith L. Shulman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith L. Shulman more than expected).

Fields of papers citing papers by Keith L. Shulman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith L. Shulman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith L. Shulman. The network helps show where Keith L. Shulman may publish in the future.

Co-authorship network of co-authors of Keith L. Shulman

This figure shows the co-authorship network connecting the top 25 collaborators of Keith L. Shulman. A scholar is included among the top collaborators of Keith L. Shulman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith L. Shulman. Keith L. Shulman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shulman, Keith L., et al.. (2015). [Population Dynamics of Cancer: a Model of Second Order Phase Transition].. PubMed. 60(4). 777–86.

Cohen, Yair, Keith L. Shulman, Menachem Ben‐Shachar, et al.. (2004). Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study. Journal of Clinical Oncology. 22(14_suppl). 3742–3742. 1 indexed citations

Cohen, Yoram, Keith L. Shulman, Menachem Ben‐Shachar, et al.. (2004). Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study. Journal of Clinical Oncology. 22(14_suppl). 3742–3742. 1 indexed citations

Tsai, Han‐Mou & Keith L. Shulman. (2003). Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. European Journal Of Haematology. 70(3). 183–185. 66 indexed citations

Sawyer, Michael B., Mark J. Ratain, Donna Bertucci, et al.. (2003). Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days. Journal of Clinical Oncology. 21(9). 1859–1865. 7 indexed citations

Kindler, Hedy L. & Keith L. Shulman. (2001). Metastatic colorectal cancer. Current Treatment Options in Oncology. 2(6). 459–471. 108 indexed citations

Ryan, Christopher W., Keith L. Shulman, Jon Richards, et al.. (2000). CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer. Investigational New Drugs. 18(2). 187–191. 2 indexed citations

Mani, Sridhar, J. W. Kugler, Rafat Ansari, et al.. (1998). Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study. Annals of Oncology. 9(9). 1035–1037. 14 indexed citations

Mani, Sridhar, Thomas D. Schiano, Juan Carlos García‐Ruiz, et al.. (1998). Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma. Investigational New Drugs. 16(3). 279–283. 12 indexed citations

10.

Shulman, Keith L., Walter M. Stadler, & Nicholas J. Vogelzang. (1996). High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The university of Chicago experience. Urology. 47(2). 194–197. 10 indexed citations

11.

Shulman, Keith L., John A. Thompson, Mark Benyunes, Thomas C. Winter, & Alexander Fefer. (1993). Adverse Reactions to Intravenous Contrast Media in Patients Treated with Interleukin-2. Journal of Immunotherapy. 13(3). 208–212. 27 indexed citations

12.

Thompson, John A., Keith L. Shulman, Mark Benyunes, et al.. (1992). Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.. Journal of Clinical Oncology. 10(6). 960–968. 53 indexed citations

13.

Shulman, Keith L. & Richard L. Schilsky. (1984). Adjuvant Therapy for Colon Cancer. New England Journal of Medicine. 311(6). 410–411. 13 indexed citations

14.

Stulberg, S. David, et al.. (1980). Breaststroker's knee: pathology, etiology, and treatment. The American Journal of Sports Medicine. 8(3). 164–171. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact